Skip to main content
. 2023 May 17;13:1147624. doi: 10.3389/fcimb.2023.1147624

Table 5.

Efficacy indicators and end point evaluation.

Cases ABCD response ECOG Fungal burden Imaging remission Prognosis
2 weeks 4 weeks End of treatment 2 weeks 4 weeks Negative or not Time, (days) 2 weeks 4 weeks Week 4 Week 8 Week 12
1 PR PR PR 2 2 Yes 8 Yes Yes Survival Survival Survival
2 PR PR PR 1 3 No / Yes Yes Survival Death# Death
3 PR PR CR 1 1 No / Yes Yes Survival Survival Survival
4 PR PR PR 1 1 No / Yes Yes Survival Survival Survival
5 PR /* / 4 / No / Yes / Death# Death Death
6 PR PR PR 2 2 No / Yes Yes Survival Survival Survival
7 PR /* / 1 / Yes 17 Yes / Death# Death Death
8 PR PR PR 3 2 Yes 33 Yes Yes Survival Survival Survival
9 PR PR PR 1 1 Yes 23 Yes Yes Survival Survival Survival

*the total treatment duration for Case 5 and Case 7 was less than 4 weeks. #Case 7 died of massive hemoptysis caused by mucormycosis, and Case 5 died due to recurrence of the primary disease after less than 4 weeks of treatment; Case 2 died due to co-bacterial infection between 4 and 8 weeks. ECOG, Eastern Cooperative Oncology Group; PR, partial response; CR, complete response. /, data not available.